Compare EVAX & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVAX | BCDA |
|---|---|---|
| Founded | 2008 | N/A |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.7M | 14.5M |
| IPO Year | 2021 | N/A |
| Metric | EVAX | BCDA |
|---|---|---|
| Price | $6.06 | $1.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $12.33 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 98.7K | 67.3K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,650,000.00 | N/A |
| Revenue This Year | $128.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 132.17 | N/A |
| 52 Week Low | $1.20 | $1.00 |
| 52 Week High | $12.15 | $3.20 |
| Indicator | EVAX | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 42.35 |
| Support Level | $5.72 | $1.26 |
| Resistance Level | $6.70 | $1.50 |
| Average True Range (ATR) | 0.50 | 0.09 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 44.97 | 25.00 |
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).